BRAINSWAY LTD/S (NASDAQ:BWAY) Given Average Recommendation of “Buy” by Analysts

BRAINSWAY LTD/S (NASDAQ:BWAY) has received a consensus rating of “Buy” from the six research firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $16.75.

Separately, Zacks Investment Research upgraded shares of BRAINSWAY LTD/S from a “sell” rating to a “hold” rating in a research report on Monday.

Shares of BWAY opened at $8.53 on Wednesday. The firm has a fifty day moving average price of $9.65. BRAINSWAY LTD/S has a 1 year low of $8.00 and a 1 year high of $12.39.

BRAINSWAY LTD/S (NASDAQ:BWAY) last announced its quarterly earnings data on Monday, August 26th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.06). The business had revenue of $5.70 million for the quarter, compared to the consensus estimate of $5.30 million. Equities research analysts anticipate that BRAINSWAY LTD/S will post -0.52 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the business. Delek Group Ltd. purchased a new stake in shares of BRAINSWAY LTD/S during the 2nd quarter worth $3,176,000. ARK Investment Management LLC purchased a new stake in shares of BRAINSWAY LTD/S during the 2nd quarter worth $863,000. Victory Capital Management Inc. purchased a new stake in shares of BRAINSWAY LTD/S during the 2nd quarter worth $157,000. Finally, Noked Capital LTD purchased a new stake in shares of BRAINSWAY LTD/S during the 2nd quarter worth $572,000. Institutional investors own 10.84% of the company’s stock.

About BRAINSWAY LTD/S

Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.

Featured Article: Profit margin is different from the revenue

Analyst Recommendations for BRAINSWAY LTD/S (NASDAQ:BWAY)

Receive News & Ratings for BRAINSWAY LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRAINSWAY LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit